Evidence map›Paper›PMID 40931253›Full record

Observational studyJournal of cancer research and clinical oncology2025

Clinical utility of comprehensive genomic profiling test for colorectal cancer: a single institution prospective observational study.

Hiroki Tanabe, Katsuyoshi Ando, Keitaro Takahashi, Tomomi Kamanaka, Sayaka Yuzawa, Junko Kikuchi, Yoshihito Ohhara, Shin Ariga, Tatsuya Shonaka, Chikayoshi Tani and 9 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hiroki TanabeGenetic Oncology Department, Asahikawa Medical University Hospital, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan. tant@asahikawa-med.ac.jp.ORCID http://orcid.org/0000-0001-9029-5081
Katsuyoshi AndoGenetic Oncology Department, Asahikawa Medical University Hospital, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan.
Keitaro TakahashiDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Tomomi KamanakaGenetic Oncology Department, Asahikawa Medical University Hospital, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan.
Sayaka YuzawaDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa, Japan.
Junko KikuchiDivision of Clinical Cancer Genomics, Hokkaido University Hospital, Sapporo, Japan.
Yoshihito OhharaDivision of Clinical Cancer Genomics, Hokkaido University Hospital, Sapporo, Japan.
Shin ArigaDivision of Clinical Cancer Genomics, Hokkaido University Hospital, Sapporo, Japan.
Tatsuya ShonakaDepartment of Surgery, Asahikawa Medical University, Asahikawa, Japan.
Chikayoshi TaniDepartment of Surgery, Asahikawa Medical University, Asahikawa, Japan.
Shin OtakeGenetic Oncology Department, Asahikawa Medical University Hospital, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan.
Takaaki SasakiGenetic Oncology Department, Asahikawa Medical University Hospital, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan.
Kenji TakahashiGenetic Oncology Department, Asahikawa Medical University Hospital, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan.
Nobuhiro UenoDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Kentaro MoriichiDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Mishie TaninoDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa, Japan.
Ichiro KinoshitaDivision of Clinical Cancer Genomics, Hokkaido University Hospital, Sapporo, Japan.
Yusuke MizukamiDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Mikihiro FujiyaDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNext-generation sequencing (NGS) has revolutionized cancer treatment by enabling comprehensive cancer genomic profiling (CGP) to guide genotype-directed therapies. While several prospective trials have demonstrated varying outcomes with CGP in patients with advanced solid tumors, its clinical utility in colorectal cancer (CRC) remains to be evaluated.

methodsWe conducted a prospective observational study of CGP in our hospital between September 2019 and March 2024. Overall survival (OS) of the patients who received CGP-based therapy and those did not was compared, and genomic variables associated with OS were evaluated.

resultsA total of 100 patients with CRC underwent CGP using four platforms. The median patient age was 67 years, and most had a good performance status. The most frequent genomic alterations were TP53 (82%), APC (82%), and KRAS (55%). Actionable mutations such as ERBB2 amplification and BRAF V600E were identified in some patients, and 9% received CGP-based therapy, including immune checkpoint inhibitors for tumor mutational burden-high or microsatellite instability-high tumors. Patients receiving CGP-based therapy had longer OS from expert panel discussion (16.0 vs. 10.8 months) compared to those who did not. Alterations in TP53, SMAD4, and NF1 were associated with worse OS. Interestingly, PTEN mutations were linked to improved survival. TP53 alterations were more common in left-sided CRC.

conclusionAlthough some patients with CRC received CGP-guided therapy, a statistically significant survival benefit was not observed. However, TP53 and SMAD4 mutations were identified as negative prognostic markers, indicating their potential as targets for future drug development.

Indexed as

Biomarkers, TumorColorectal NeoplasmsAdultAgedAged, 80 and overFemaleGenomicsHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationPrognosisProspective StudiesBiomarkers, TumorCancer genomicsColorectal carcinomaNGSPrognostic markersTumor biomarkers

Identifiers

PMID40931253
PMCPMC12423004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.